These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34301487)

  • 1. Efficacy and Safety of Homoharringtonine for the Treatment of Acute Myeloid Leukemia: A Meta-analysis.
    Mi R; Zhao J; Chen L; Wei X; Liu J; Wei X
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e752-e767. PubMed ID: 34301487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of a homoharringtonine-based protocol for children with acute myeloid leukemia: A retrospective study in China.
    Tang Y; Luo C; Shen S; Xue H; Pan C; Hu W; Chen X; Cai J; Chen J; Tang J
    Pediatr Hematol Oncol; 2021 Mar; 38(2):97-107. PubMed ID: 33016804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies.
    Kantarjian H; O'Brien S; Jabbour E; Barnes G; Pathak A; Cortes J
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):13-21. PubMed ID: 25458084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia.
    Chen X; Tang Y; Chen J; Chen R; Gu L; Xue H; Pan C; Tang J; Shen S
    Front Med; 2019 Jun; 13(3):378-387. PubMed ID: 30635781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways.
    Shi X; Zhu M; Gong Z; Yang T; Yu R; Wang J; Zhang Y
    Food Chem Toxicol; 2020 Feb; 136():110960. PubMed ID: 31726078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
    Kang JS; Lee J; Nam LB; Yoo OK; Pham KT; Duong TH; Keum YS
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2189-2196. PubMed ID: 31270017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
    Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
    Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.
    Tang J; Liu Y; Chen J; Xue H; Pan C; Gu L
    Int J Hematol; 2011 May; 93(5):610-617. PubMed ID: 21509439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
    Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
    Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.
    Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
    Leukemia; 1992 Nov; 6(11):1185-8. PubMed ID: 1434802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
    Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.
    Gu LF; Zhang WG; Wang FX; Cao XM; Chen YX; He AL; Liu J; Ma XR
    J Cancer Res Clin Oncol; 2011 Jun; 137(6):997-1003. PubMed ID: 21152934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Tong H; Ren Y; Zhang F; Jin J
    Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial.
    Jin J; Wang JX; Chen FF; Wu DP; Hu J; Zhou JF; Hu JD; Wang JM; Li JY; Huang XJ; Ma J; Ji CY; Xu XP; Yu K; Ren HY; Zhou YH; Tong Y; Lou YJ; Ni WM; Tong HY; Wang HF; Mi YC; Du X; Chen BA; Shen Y; Chen Z; Chen SJ
    Lancet Oncol; 2013 Jun; 14(7):599-608. PubMed ID: 23664707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia.
    Zhang W; Lu Y; Zhen T; Chen X; Zhang M; Liu P; Weng X; Chen B; Wang Y
    Front Med; 2019 Jun; 13(3):388-397. PubMed ID: 30206768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
    Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
    J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells.
    Chen J; Mu Q; Li X; Yin X; Yu M; Jin J; Li C; Zhou Y; Zhou J; Suo S; Lu D; Jin J
    Oncotarget; 2017 Jun; 8(25):40318-40326. PubMed ID: 28454099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homoharringtonine deregulates
    Chen XJ; Zhang WN; Chen B; Xi WD; Lu Y; Huang JY; Wang YY; Long J; Wu SF; Zhang YX; Wang S; Li SX; Yin T; Lu M; Xi XD; Li JM; Wang KK; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2220-2225. PubMed ID: 30659143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway.
    Ling Q; Li F; Zhang X; Mao S; Lin X; Pan J; Ye W; Wei W; Qian Y; Hu C; Huang X; Wang J; Wang H; Huang J; Wang Y; Jin J
    EBioMedicine; 2021 Jul; 69():103441. PubMed ID: 34166980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydropyrimidinase-like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia.
    Li F; Ling Q; Lian J; Chen Y; Hu C; Yang M; Zhang X; Li C; Mao S; Ye W; Li X; Lin X; Wei W; Huang X; Pan J; Qian Y; Wang J; Lu Y; Jin J
    Cancer Med; 2023 Apr; 12(7):8319-8330. PubMed ID: 36621846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.